omeprazole and Rheumatoid Arthritis studies

Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.

Research Excerpts

Excerpt	Relevance	Reference
"We report two cases of hydroxychloroquine-induced hyperpigmentation presenting in a 50-year-old Caucasian female (case 1) and a 78-year-old female (case 2), both receiving 400 mg per day."	7.74	Hydroxychloroquine-induced hyperpigmentation: the staining pattern. ( Ferringer, T; Lountzis, NI; Puri, PK; Tyler, W, 2008)
" In this open-label study, the effect of lansoprazole 30 mg qd and naproxen 500 mg bid on the pharmacokinetic profile of methotrexate was investigated."	6.71	Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis. ( Amer, F; Andhivarothai, N; Kukulka, MJ; Vakily, M, 2005)
"This therapeutic protein-drug interaction study evaluated the disease-mediated effect of sirukumab (anti-interleukin 6 [anti-IL-6] monoclonal antibody) on the pharmacokinetics of the cytochrome P450 (CYP) probe substrates midazolam (CYP3A), omeprazole (CYP2C19), warfarin (CYP2C9), and caffeine (CYP1A2) in patients with active rheumatoid arthritis (RA)."	5.20	Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach. ( Chen, D; Davis, HM; de Vries, DE; Leon, F; Marciniak, SJ; Xu, Z; Zhou, H; Zhuang, Y, 2015)
"5) with rheumatoid arthritis or osteoarthritis, requiring chronic intake of NSAIDs (at least 8 weeks prior to the start of the study), were randomised and enrolled to receive either 40 mg pantoprazole (n=70) or placebo (n=34) once daily, for 12 weeks."	5.09	Efficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-inflammatory drugs: a prospective, placebo-controlled, double-blind, parallel-group study. ( Bianchi Porro, G; Imbesi, V; Lazzaroni, M; Montrone, F; Santagada, T, 2000)
"Findings will provide timely information on the safety, efficacy, and optimal dosing of t-PA to treat moderate/severe COVID-19-induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634)."	4.21	( Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y, 2022)
"Results of the CONDOR study suggest that in osteoarthritis and rheumatoid arthritis patients at elevated risk of gastrointestinal (GI) events, treatment with celecoxib, a cyclooxygenase (COX)-2 selective non-steroidal anti-inflammatory drug (NSAID), demonstrated significantly lower toxicity in the upper and lower (GI) tract when compared to the non-selective NSAID diclofenac plus a proton-pump-inhibitor (PPI), omeprazole."	3.81	How to mechanistically explain the CONDOR study data. ( Buttgereit, F; Spies, CM; Stemmler, E, 2015)
"We report two cases of hydroxychloroquine-induced hyperpigmentation presenting in a 50-year-old Caucasian female (case 1) and a 78-year-old female (case 2), both receiving 400 mg per day."	3.74	Hydroxychloroquine-induced hyperpigmentation: the staining pattern. ( Ferringer, T; Lountzis, NI; Puri, PK; Tyler, W, 2008)
"To carry out a economic evaluation of diclofenac/misoprostol in the treatment of rheumatoid arthritis and osteoartritis when comparing with diclofenac alone, diclofenac + omeprazol, and diclofenac + ranitidine."	3.70	[Economic evaluation of the use of diclofenac/misoprostol in the treatment of osteoarticular diseases]. ( Soto Alvarez, J, 2000)
" The ulcers became scars after treatment with omeprazole, which cause in severe pyloric stenosis."	3.69	Endoscopic hydrostatic balloon dilation of ulcer-induced pyloric stenosis in rheumatoid arthritis and secondary amyloidosis. ( Aoyagi, K; Eguchi, K; Fujishima, M; Hizawa, K; Ohta, Y; Satou, H, 1997)
" In this open-label study, the effect of lansoprazole 30 mg qd and naproxen 500 mg bid on the pharmacokinetic profile of methotrexate was investigated."	2.71	Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis. ( Amer, F; Andhivarothai, N; Kukulka, MJ; Vakily, M, 2005)
" pylori status on the incidence of gastrointestinal (GI) events in rheumatic patients receiving longterm conventional nonsteroidal antiinflammatory drug (NSAID) therapy combined with omeprazole."	2.70	Influence of Helicobacter pylori eradication therapy on the occurrence of gastrointestinal events in patients treated with conventional nonsteroidal antiinflammatory drugs combined with omeprazole. ( Bannwarth, B; Barthelemy, P; Caekaert, A; Dorval, E, 2002)

Research

Studies (23)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Change From Baseline in C-Reactive Protein to Month 6/ET

Change From Baseline in Ferretin to Month 6/ET

Change From Baseline in Hematocrit at Month 6/ET

Change From Baseline in Hemoglobin at Month 6/ET

Change From Baseline in Iron Binding Capacity to Month 6/ET

Change From Baseline in Patient's Global Arthritis Assessment at Month 6/Early Termination (ET)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (4.35)	18.7374
1990's	2 (8.70)	18.2507
2000's	15 (65.22)	29.6817
2010's	4 (17.39)	24.3611
2020's	1 (4.35)	2.80

Authors	Studies
Nese, M	1
Riboli, G	1
Brighetti, G	1
Sassi, V	1
Camela, E	1
Caselli, G	1
Sassaroli, S	1
Borlimi, R	1
Aucoin, M	1
Cooley, K	1
Saunders, PR	1
Carè, J	1
Anheyer, D	1
Medina, DN	1
Cardozo, V	1
Remy, D	1
Hannan, N	1
Garber, A	1
Velayos, M	1
Muñoz-Serrano, AJ	1
Estefanía-Fernández, K	1
Sarmiento Caldas, MC	1
Moratilla Lapeña, L	1
López-Santamaría, M	1
López-Gutiérrez, JC	1
Li, J	1
Zhang, J	1
Shen, S	1
Zhang, B	2
Yu, WW	1
Toyoda, H	1
Huang, DQ	1
Le, MH	1
Nguyen, MH	1
Huang, R	1
Zhu, L	1
Wang, J	6
Xue, L	1
Liu, L	2
Yan, X	2
Huang, S	1
Li, Y	6
Xu, T	1
Li, C	2
Ji, F	1
Ming, F	1
Zhao, Y	2
Cheng, J	1
Wang, Y	3
Zhao, H	1
Hong, S	1
Chen, K	2
Zhao, XA	1
Zou, L	1
Sang, D	1
Shao, H	1
Guan, X	1
Chen, X	2
Chen, Y	4
Wei, J	1
Zhu, C	1
Wu, C	1
Moore, HB	1
Barrett, CD	1
Moore, EE	1
Jhunjhunwala, R	1
McIntyre, RC	1
Moore, PK	1
Hajizadeh, N	1
Talmor, DS	1
Sauaia, A	1
Yaffe, MB	1
Liu, C	3
Lin, Y	1
Dong, Y	1
Wu, Y	1
Bao, Y	1
Yan, H	2
Ma, J	1
Fernández-Cuadros, ME	1
Albaladejo-Florín, MJ	1
Álava-Rabasa, S	1
Usandizaga-Elio, I	1
Martinez-Quintanilla Jimenez, D	1
Peña-Lora, D	1
Neira-Borrajo, I	1
López-Muñoz, MJ	1
Rodríguez-de-Cía, J	1
Pérez-Moro, OS	1
Abdallah, M	1
Alsaleh, H	1
Baradwan, A	1
Alfawares, R	1
Alobaid, A	1
Rasheed, A	1
Soliman, I	1
Wendel Garcia, PD	1
Fumeaux, T	1
Guerci, P	1
Heuberger, DM	1
Montomoli, J	2
Roche-Campo, F	1
Schuepbach, RA	1
Hilty, MP	1
Poloni, TE	1
Carlos, AF	1
Cairati, M	1
Cutaia, C	1
Medici, V	1
Marelli, E	1
Ferrari, D	1
Galli, A	1
Bognetti, P	1
Davin, A	1
Cirrincione, A	1
Ceretti, A	1
Cereda, C	1
Ceroni, M	1
Tronconi, L	1
Vitali, S	1
Guaita, A	1
Leeds, JS	1
Raviprakash, V	1
Jacques, T	1
Scanlon, N	1
Cundall, J	1
Leeds, CM	1
Riva, A	1
Gray, EH	1
Azarian, S	1
Zamalloa, A	1
McPhail, MJW	1
Vincent, RP	1
Williams, R	1
Chokshi, S	1
Patel, VC	1
Edwards, LA	1
Alqarawi, W	1
Birnie, DH	1
Golian, M	1
Nair, GM	1
Nery, PB	1
Klein, A	1
Davis, DR	1
Sadek, MM	1
Neilipovitz, D	1
Johnson, CB	1
Green, MS	1
Redpath, C	1
Miller, DC	1
Beamer, P	1
Billheimer, D	1
Subbian, V	1
Sorooshian, A	1
Campbell, BS	1
Mosier, JM	1
Novaretti, JV	1
Astur, DC	1
Cavalcante, ELB	1
Kaleka, CC	1
Amaro, JT	1
Cohen, M	1
Huang, W	1
Li, T	1
Ling, Y	1
Qian, ZP	1
Zhang, YY	1
Huang, D	1
Xu, SB	1
Liu, XH	1
Xia, L	1
Yang, Y	3
Lu, SH	1
Lu, HZ	1
Zhang, R	2
Ma, JX	1
Tang, S	1
Li, CM	1
Wan, J	1
Wang, JF	1
Ma, JQ	1
Luo, JJ	1
Chen, HY	2
Mi, SL	1
Chen, SY	1
Su, YG	1
Ge, JB	1
Milheiro, SA	1
Gonçalves, J	1
Lopes, RMRM	1
Madureira, M	1
Lobo, L	1
Lopes, A	1
Nogueira, F	1
Fontinha, D	1
Prudêncio, M	1
M Piedade, MF	1
Pinto, SN	1
Florindo, PR	1
Moreira, R	1
Castillo-Lora, J	1
Delley, MF	1
Laga, SM	1
Mayer, JM	1
Sutjarit, N	1
Thongon, N	1
Weerachayaphorn, J	1
Piyachaturawat, P	1
Suksamrarn, A	1
Suksen, K	1
Papachristou, DJ	1
Blair, HC	1
Hu, Y	1
Shen, P	1
Zeng, N	1
Wang, L	3
Yan, D	1
Cui, L	1
Yang, K	2
Zhai, C	1
Yang, M	1
Lao, X	1
Sun, J	1
Ma, N	1
Wang, S	1
Ye, W	1
Guo, P	1
Rahimi, S	1
Singh, MP	1
Gupta, J	1
Nakanishi, I	1
Ohkubo, K	1
Shoji, Y	1
Fujitaka, Y	1
Shimoda, K	1
Matsumoto, KI	1
Fukuhara, K	1
Hamada, H	1
van der Boom, T	1
Gruppen, EG	1
Lefrandt, JD	1
Connelly, MA	1
Links, TP	1
Dullaart, RPF	1
Berry, JD	1
Bedlack, R	1
Mathews, D	1
Agnese, W	1
Apple, S	1
Meloncelli, S	1
Divizia, M	1
Germani, G	1
Adefegha, SA	1
Bottari, NB	1
Leal, DB	1
de Andrade, CM	1
Schetinger, MR	1
Martínez-Velasco, A	1
Perez-Ortiz, AC	1
Antonio-Aguirre, B	1
Martínez-Villaseñor, L	1
Lira-Romero, E	1
Palacio-Pastrana, C	1
Zenteno, JC	1
Ramirez, I	1
Zepeda-Palacio, C	1
Mendoza-Velásquez, C	1
Camacho-Ordóñez, A	1
Ortiz Bibriesca, DM	1
Estrada-Mena, FJ	1
Martin, BL	1
Thompson, LC	1
Kim, YH	2
Snow, SJ	1
Schladweiler, MC	1
Phillips, P	1
Harmon, M	1
King, C	1
Richards, J	1
George, I	1
Haykal-Coates, N	1
Gilmour, MI	1
Kodavanti, UP	1
Hazari, MS	1
Farraj, AK	1
Shen, Z	1
Zou, Y	1
Gao, K	1
Lazar, S	1
Wurtzel, JGT	1
Ma, P	1
Goldfinger, LE	1
Vukelic, M	1
Laloo, A	1
Kyttaris, VC	1
Chen, R	1
Chen, J	2
Xun, J	1
Hu, Z	1
Huang, Q	2
Steinhart, C	1
Shen, Y	1
Lu, H	1
Mansuri, A	1
Lokhande, K	1
Kore, S	1
Gaikwad, S	1
Nawani, N	1
Swamy, KV	1
Junnarkar, M	1
Pawar, S	1
Shaheen, MY	1
Basudan, AM	1
Niazy, AA	1
van den Beucken, JJJP	1
Jansen, JA	1
Alghamdi, HS	1
Gao, Q	2
Guo, X	1
Cao, Y	1
Jia, X	1
Xu, S	1
Lu, C	2
Zhu, H	2
Melku, M	1
Abebe, G	1
Teketel, A	1
Asrie, F	1
Yalew, A	1
Biadgo, B	1
Kassa, E	1
Damtie, D	1
Anlay, DZ	1
Ahmed, MFE	1
Ramadan, H	1
Seinige, D	1
Kehrenberg, C	1
Abd El-Wahab, A	1
Volkmann, N	1
Kemper, N	1
Schulz, J	1
Hu, MY	1
Wu, YN	1
McEvoy, MP	1
Wang, YF	1
Cong, WL	1
Liu, LP	1
Li, XX	1
Zhou, CL	1
Chen, WM	1
Wei, KL	1
Tung, SY	1
Shen, CH	1
Chang, TS	1
Yen, CW	1
Hsieh, YY	1
Chiu, WN	1
Hu, JH	1
Lu, SN	1
Hung, CH	1
Alakavuklar, MA	1
Fuqua, C	1
Luo, KL	1
Underwood, RS	1
Greenwald, I	1
Elashiry, MM	1
Elashiry, M	1
Zeitoun, R	1
Elsayed, R	1
Tian, F	1
Saber, SE	1
Elashry, SH	1
Tay, FR	1
Cutler, CW	1
O'Dowd, A	1
Maciel, M	1
Poole, ST	1
Jobling, MG	1
Rollenhagen, JE	1
Woods, CM	1
Sincock, SA	1
McVeigh, AL	1
Gregory, MJ	1
Maves, RC	1
Prouty, MG	1
Holmes, RK	1
Savarino, SJ	1
Mor, MK	1
Palevsky, PM	1
Kaufman, JS	1
Thiessen Philbrook, H	1
Weisbord, SD	1
Parikh, CR	1
John, CM	1
Phillips, NJ	1
Jarvis, GA	1
Zhu, Y	1
Kilburn, S	1
Kapoor, M	1
Chaturvedi, S	1
Shaw, KJ	1
Chaturvedi, V	1
Kong, X	1
Zhang, T	1
Xiao, H	1
Feng, X	1
Tu, H	1
Feng, J	1
Sabet, M	1
Tarazi, Z	1
Griffith, DC	1
Nguyen, F	1
Guan, P	1
Guerrero, DT	1
Kolla, V	1
Naraparaju, K	1
Perry, LM	1
Soberman, D	1
Pressly, BB	1
Alferiev, IS	1
Chorny, M	1
Brodeur, GM	1
Gao, X	2
Cheng, YH	1
Enten, GA	1
DeSantis, AJ	1
Gaponenko, V	1
Majetschak, M	1
Kim, DY	1
Choi, MJ	1
Ko, TK	1
Lee, NH	1
Kim, OH	1
Cheon, HG	1
Cai, H	1
Yip, V	1
Lee, MV	1
Wong, S	1
Saad, O	1
Ma, S	1
Ljumanovic, N	1
Khojasteh, SC	1
Kamath, AV	1
Shen, BQ	1
Cuypers, ML	1
Chanteux, H	1
Gillent, E	1
Bonnaillie, P	1
Saunders, K	1
Beckers, C	1
Delatour, C	1
Dell'Aiera, S	1
Ungell, AL	1
Nicolaï, J	1
Knapp, AK	1
Chen, A	1
Griffin-Nolan, RJ	1
Baur, LE	1
Carroll, CJW	1
Gray, JE	1
Hoffman, AM	1
Li, X	4
Post, AK	1
Slette, IJ	1
Collins, SL	1
Luo, Y	1
Smith, MD	1
Temitayo, GI	1
Olawande, B	1
Emmanuel, YO	1
Timothy, AT	1
Kehinde, O	1
Susan, LF	1
Ezra, L	1
Joseph, OO	1
Lev, S	1
Desmarini, D	1
Liuwantara, D	1
Sorrell, TC	1
Hawthorne, WJ	1
Djordjevic, JT	1
Verso, MG	1
Costantino, C	1
Marrella, A	1
Immordino, P	1
Vitale, F	1
Amodio, E	1
Wang, YD	1
Yao, WL	1
Xin, ZM	1
Han, TT	1
Wang, ZG	1
Chen, L	1
Cai, C	1
Zhang, Y	4
Ba, D	1
Wen, S	1
Tian, Q	1
Lv, W	1
Cheng, G	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At Hig[NCT00141102]	Phase 4	4,484 participants (Actual)	Interventional	2005-10-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	mg/dL (Least Squares Mean)
Celecoxib	0.058
Oral Diclofenac Plus Omeprazole	0.073

Intervention	ug/dL (Least Squares Mean)
Celecoxib	-3.396
Oral Diclofenac Plus Omeprazole	-1.990

Intervention	percent (Least Squares Mean)
Celecoxib	-0.306
Oral Diclofenac Plus Omeprazole	-1.425

Intervention	grams (g)/deciliter (dL) (Least Squares Mean)
Celecoxib	-0.017
Oral Diclofenac Plus Omeprazole	-0.423

Intervention	microgram (ug)/dL (Least Squares Mean)
Celecoxib	2.517
Oral Diclofenac Plus Omeprazole	1.952

"Subjects rated response to question: Considering all the ways the osteoarthritis or rheumatoid arthritis affects you, how are you doing today? using a 1 to 5 grading scale where 1=very good and 5=very poor." (NCT00141102)
Timeframe: Month 6/Early Termination (ET)

Number of Subjects Alive at the Post Trial Interview

Intervention	scores on a scale (Least Squares Mean)
Celecoxib	0.754
Oral Diclofenac Plus Omeprazole	0.773

Interview occurred via telephone to obtain follow-up mortality and hospitalization information. (NCT00141102)
Timeframe: 6 months following last dose

Number of Subjects Hospitalized in Last 6 Months at the Post Trial Interview

Intervention	participants (Number)
Celecoxib	2018
Oral Diclofenac Plus Omeprazole	2023

Interview occurred via telephone to obtain follow-up mortality and hospitalization information. (NCT00141102)
Timeframe: 6 months following last dose

Number of Subjects With a Clinically Significant Decrease From Baseline in Hematocrit and/or Hemoglobin

Intervention	participants (Number)
Celecoxib	82
Oral Diclofenac Plus Omeprazole	79

A clinically significant decrease from baseline was defined as a fall in hematocrit > = 10 percentage points and/or hemoglobin > = 2 g/dL. (NCT00141102)
Timeframe: 6 month treatment duration

Number of Subjects With Clinically Significant Upper and/or Lower Gastrointestinal Events (CSULGIEs)

Intervention	participants (Number)
Celecoxib	45
Oral Diclofenac Plus Omeprazole	123

CSULGIE=any of the following: gastroduodenal (GD) hemorrhage; gastric outlet obstruction; GD, small or large bowel perforation; small or large bowel hemorrhage; clinically significant anemia of defined GI origin; acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage; clinically significant anemia of presumed occult GI origin including possible small bowel blood loss. Subjects were assessed by an independent GI Events Adjudication Committee, who were blinded to study treatment assignments. (NCT00141102)
Timeframe: 6 month treatment duration

Number of Subjects With CSULGIES or Symptomatic Ulcers (SUs)

Intervention	participants (Number)
Celecoxib	20
Oral Diclofenac Plus Omeprazole	81

CSULGIE=any of the following: GD hemorrhage; gastric outlet obstruction; GD, small or large bowel perforation; small or large bowel hemorrhage; clinically significant anemia of defined GI origin; acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage; clinically significant anemia of presumed occult GI origin including possible small bowel blood loss. Subjects with evaluation at an event visit and found to have an ulcer on endoscopy, but did not meet any criteria considered for the primary endpoint by the GI committee were designated as having an SU. (NCT00141102)
Timeframe: 6 month treatment duration

Number of Subjects With Moderate to Severe Abdominal Symptoms

Intervention	participants (Number)
Celecoxib	25
Oral Diclofenac Plus Omeprazole	92

"Abdominal symptoms were defined by the Medical Dictionary for Regulatory Activities MedDRA System Organ Class (SOC) 'Gastrointestinal Disorders' and keeping high level group term (HLGT) equal to Gastrointestinal Signs and Symptoms." (NCT00141102)
Timeframe: 6 month treatment duration

Number of Subjects With SUs

Intervention	participants (Number)
Celecoxib	132
Oral Diclofenac Plus Omeprazole	162

Subjects with evaluation at an event visit and found to have an ulcer on endoscopy, but did not meet any criteria considered for the primary endpoint by the GI committee were designated as having an SU. (NCT00141102)
Timeframe: 6 month treatment duration

Number of Subjects Withdrawn Due to GI Adverse Events (AEs)

Intervention	participants (Number)
Celecoxib	5
Oral Diclofenac Plus Omeprazole	11

"GI AEs were defined using MedDRA SOC Gastrointestinal Disorders but excluding the following HLGTs: Benign Neoplasms Gastrointestinal; Dental and Gingival Conditions; Oral Soft Tissue Conditions; Salivary Gland Conditions; and Tongue Conditions." (NCT00141102)
Timeframe: 6 month treatment duration

Change From Baseline in Hepatic Measures of GGT, AST or ALT to Month 6/ET

Number of Subjects With CSULGIEs by History of GD Ulceration

Intervention	participants (Number)
Celecoxib	114
Oral Diclofenac Plus Omeprazole	167

Intervention	IU/L (Least Squares Mean)
	GGT	AST	ALT
Celecoxib	-2.689	-0.901	-1.151
Oral Diclofenac Plus Omeprazole	7.455	1.490	5.213

Number of Subjects With Hepatic AEs in Gamma Glutamyl-Transferase (GGT), Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) of 3 Times the Upper Limit of Normal (ULN)

Intervention	participants (Number)
	History of GD Ulceration (n=395, 400)	No History of GD Ulceration (n=1843, 1846)
Celecoxib	7	13
Oral Diclofenac Plus Omeprazole	13	68

GGT ULN was 49 international units (IU)/liter (L) for females and 61 IU/L for males, AST ULN was 37 IU/L for females and 39 IU/L for males, and ALT ULN was 43 IU/L for females and 45 IU/L for males. (NCT00141102)
Timeframe: 6 month treatment duration

Article	Year
Zeitschrift fur Gesundheitswissenschaften = Journal of public health, 2022, Volume: 30, Issue:2 Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain;	2022
[Treatment of peptic ulcer related to rheumatic diseases]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60, Issue:8 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Histamine H2 Antagonists; Humans; Lu	2002
Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health technology assessment (Winchester, England), 2008, Volume: 12, Issue:11 Topics: Anti-Ulcer Agents; Arthritis, Rheumatoid; Cost-Benefit Analysis; Cyclooxygenase 2 Inhibitors; Gastro	2008
Nonsteroidal antiinflammatory drugs and the gastrointestinal tract. The Gastroenterologist, 1994, Volume: 2, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Digestive System; Gastrointestinal H	1994

Article	Year
Zeitschrift fur Gesundheitswissenschaften = Journal of public health, 2022, Volume: 30, Issue:2 Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain;	2022
Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach. Journal of clinical pharmacology, 2015, Volume: 55, Issue:12 Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Rheum	2015
Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet (London, England), 2010, Jul-17, Volume: 376, Issue:9736 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Celecoxib;	2010
Influence of Helicobacter pylori eradication therapy on the occurrence of gastrointestinal events in patients treated with conventional nonsteroidal antiinflammatory drugs combined with omeprazole. The Journal of rheumatology, 2002, Volume: 29, Issue:9 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Confidence Intervals; D	2002
Economic analysis of celecoxib versus diclofenac plus omeprazole for the treatment of arthritis in patients at risk of ulcer disease. Alimentary pharmacology & therapeutics, 2003, Jul-15, Volume: 18, Issue:2 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Celecoxib;	2003
Preventive therapy for non-steroidal anti-inflammatory drug-induced ulcers in Japanese patients with rheumatoid arthritis: the current situation and a prospective controlled-study of the preventive effects of lansoprazole or famotidine. Alimentary pharmacology & therapeutics, 2005, Volume: 21 Suppl 2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer A	2005
Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis. Journal of clinical pharmacology, 2005, Volume: 45, Issue:10 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Anti-Inflammatory Agents	2005
Efficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-inflammatory drugs: a prospective, placebo-controlled, double-blind, parallel-group study. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2000, Volume: 32, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-	2000
Quality of life in chronic NSAID users: a comparison of the effect of omeprazole and misoprostol. Scandinavian journal of rheumatology, 2001, Volume: 30, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Inflammatory Agents, Non-Ster	2001
[Stomach tolerance of nonsteroidal antirheumatic drugs: comparative endoscopic study]. Zeitschrift fur Rheumatologie, 1987, Volume: 46 Suppl 1 Topics: Adult; Alprostadil; Antacids; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspiri	1987

Article	Year
How to mechanistically explain the CONDOR study data. Medical hypotheses, 2015, Volume: 84, Issue:1 Topics: Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Intestinal Mucosa	2015
Hydroxychloroquine-induced hyperpigmentation: the staining pattern. Journal of cutaneous pathology, 2008, Volume: 35, Issue:12 Topics: Aged; Antacids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents	2008
NSAIDs and risk of lower gastrointestinal bleeding. Lancet (London, England), 2010, Jul-17, Volume: 376, Issue:9736 Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Celecoxib; Coloni	2010
Cost-effectiveness analysis of NSAIDs, NSAIDs with concomitant therapy to prevent gastrointestinal toxicity, and COX-2 specific inhibitors in the treatment of rheumatoid arthritis. Rheumatology international, 2005, Volume: 25, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Cost-Benefit Anal	2005
[Selective cox-2 inhibitors. Better tolerance than NSAID plus antacid]. MMW Fortschritte der Medizin, 2004, Apr-08, Volume: 146, Issue:15 Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib;	2004
Disease-modifying anti-rheumatic drugs are only one of a number of potential causes of myelosuppression: a careful drug history is necessary to elucidate the cause of an adverse event. Rheumatology (Oxford, England), 2006, Volume: 45, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Infective Agents; Antirheumatic Agents; Arthriti	2006
Endoscopic hydrostatic balloon dilation of ulcer-induced pyloric stenosis in rheumatoid arthritis and secondary amyloidosis. Surgical endoscopy, 1997, Volume: 11, Issue:6 Topics: Amyloidosis; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Biop	1997
[Economic evaluation of the use of diclofenac/misoprostol in the treatment of osteoarticular diseases]. Anales de medicina interna (Madrid, Spain : 1984), 2000, Volume: 17, Issue:9 Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Cost-Benefit Anal	2000
Delayed healing of gastric ulcers in adjuvant arthritis rats: role of acid secretion and basic fibroblast growth factor. Digestion, 2001, Volume: 63, Issue:3 Topics: Animals; Arthritis, Rheumatoid; Blotting, Western; Disease Models, Animal; Fibroblast Growth Factors	2001
Drugs versus diets: disillusions with Dutch health care. Acta biotheoretica, 2001, Volume: 49, Issue:2 Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumat	2001

omeprazole and Rheumatoid Arthritis